



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

November 19, 2010

Dr. Friedhelm Blobel, Ph.D.  
Chief Executive Officer  
SciClone Pharmaceuticals, Inc.  
950 Tower Lane, Suite 900  
Foster City, CA 94404

**Re: SciClone Pharmaceuticals, Inc.  
Form 10-K for the year ended December 31, 2009  
Definitive Proxy Statement on Schedule 14A filed April 30, 2010  
File No. 000-19825**

Dear Dr. Blobel:

We have reviewed your response letter dated November 16, 2010 to our comment letter dated November 2, 2010 and have the following comments.

Please respond to this letter within ten business days by amending your filing pursuant to comment 1, comment 2, and comment 3 and providing the additional information requested by comment 4 below. Please furnish us a letter on EDGAR under the form type label CORRESP that keys your responses to our comments.

Form 10-K for the year ended December 31, 2009

1. Please amend your 2009 Form 10-K to include the proposed disclosure provided in your letter dated October 15, 2010 in response to prior comment 1, prior comment 3, and prior comment 5 from our initial comment letter dated September 21, 2010.

Item 1. Business

2. We note your response to comment 1. Please amend your 2009 Form 10-K to include the proposed disclosure you have provided in response to this comment.

DEF14A

Annual Cash Incentives, page 36

3. We note your response to comment 2. We view the specific performance goals and underlying performance targets for your annual cash incentive plan as material information that should be included in your Compensation Discussion and Analysis disclosure to ensure investors' understanding of your executive compensation practices. Please amend your 2009 Form 10-K to include the proposed disclosure you have provided in response to this comment.

Long-Term Cash Incentives, page 37

4. We note your response to comment 3. Unless you can provide an unqualified confirmation that you will disclose all of the specific annual performance goals and the performance targets for these goals at the end of the performance period, please provide a detailed competitive harm analysis in support of your omission of any performance goals or targets pursuant to Instruction 4 to Item 402(b) of Regulation S-K. Your analysis should identify the competitively harmful information and demonstrate how the information could be harmful to your company.

We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable Exchange Act rules require. Since the company and its management are in possession of all facts relating to a company's disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made.

You may contact Bryan Pitko, Staff Attorney at (202) 551-3203 with questions on any of the comments. In this regard, do not hesitate to contact me at (202) 551-3715.

Sincerely,

Jeffrey Riedler  
Assistant Director

cc: Howard Clowes  
DLA Piper LLP (US)  
555 Mission Street, Suite 2400  
San Francisco, CA 94105